Topic

Science

Findings worth opening at the source, with the caveats left intact.

A smartphone app lets epilepsy patients teach their monitor, cutting false alarms

In a small hospital study at the University of Pennsylvania, patients could ask an app about their own brain activity and label its seizure alerts as right or wrong. The detector learned from that feedback and its false alarms fell by about 80%.

Fewer false alerts could make seizure monitoring less stressful, and it points to devices that learn from the people who use them.

Small clinical study in a hospital setting; larger trials are still needed.

FDA approves an added immunotherapy for one type of stage III colon cancer

On October 8 the FDA approved atezolizumab alongside standard chemotherapy after surgery for stage III colon cancer with a specific tumor trait called mismatch repair deficiency. In a trial of 711 adults, the risk of the cancer returning or of death was about half that of chemotherapy alone.

It gives doctors a proven new option right after surgery, when the goal is keeping the cancer from coming back.

Applies only to tumors with mismatch repair deficiency.

AI-assisted eye screening nearly doubled follow-up care for people with diabetes in Tanzania

In a trial of 2,378 people at 24 Tanzanian hospitals, those screened with AI support were far more likely to see a specialist within eight weeks (35.9% versus 18.2%) and got there about 26 days sooner.

Diabetes can quietly damage sight, and getting people to the eye clinic quickly is often what saves it.

Researchers note that screening only helps if specialist care and treatment are also available.

Bleached coral recovered in weeks after simply touching a healthy piece of itself

Stanford researchers found that when a bleached coral fragment rests against a healthy fragment from the same colony, their tissues link up and helpful algae flow across. About a week of contact was enough, and the bleached pieces fully recovered in roughly seven weeks while separated ones died.

Bleaching is one of the biggest threats to reefs, and a fast natural route to recovery gives restoration teams a new idea to build on.

Lab study with small numbers of corals, and it only worked between genetically identical pieces.

A brighter rapid test could spot syphilis sooner, before a patient leaves the clinic

Penn State researchers built a one-step test that looks for both kinds of syphilis antibodies at once. Layered gold-and-silver particles make the line easier to see: on 36 clinical specimens the lines were 19% to 46% stronger than with ordinary gold, with the biggest gain at the faintest levels, when an infection is early or fading after treatment.

Syphilis can be cured, and finding a quiet early infection in one visit can protect a patient, a partner and a pregnancy.

A pilot device, not an approved test. Larger studies and regulatory review are still ahead.

Image: Medical Xpress (Olivia Newton-John Cancer Research Institute)

A comparison of three mRNA vaccines finds they do not fade the same way in human blood

Researchers at the Olivia Newton-John Cancer Research Institute and the Doherty Institute looked at 327 blood samples from 73 people who received the Moderna, Pfizer, or an investigational COVID-19 mRNA vaccine. The packages did not hold together equally: much of the circulating mRNA in the Moderna and Pfizer groups was already in pieces, and a closer look at six Moderna recipients found the message more broken near one end. The team says the comparison could guide sturdier vaccines, including ones being explored for cancer.

Knowing which vaccine packages last longer in the bloodstream gives designers a concrete thing to improve.

This compares vaccines people already received. It does not test a new shot, and the hope of lower doses is an inference, not a result of the study.

Image: American Society of Anesthesiologists

Six hospitals cut anesthetic emissions 45% and kept the same safety checks

A study presented at the anesthesiology meeting in San Diego followed 145,917 anesthetic episodes at a six-site academic system tied to Virginia Tech Carilion. After clinicians used more sevoflurane and intravenous anesthesia, lowered fresh-gas flow, and got feedback on their own emissions, average emissions per case fell from 57.6 to 31.6 kilograms of CO2 equivalent. Desflurane use fell from 23.8% of cases to 9.81%. Inhaled-anesthetic spending went from $628,588 in 2021 to $379,010 in 2024. Recovery time, hospital stays, re-intubation, awareness, and nausea did not increase.

Operating rooms can lighten their climate cost with choices clinicians already know how to make, without asking patients to accept a riskier anesthetic.

A before-and-after report from one health system, presented at a meeting, not a randomized trial or a journal paper. The release's "in half" wording is ahead of the 45% average; the system says it later passed a 50% goal.

Image: Nagoya University

Nagoya researchers trace a backup way neurons clear a protein tied to ALS

A Nagoya University team reports, in EMBO reports, a route motor neurons use to clear TDP-43, a protein that clumps in the cytoplasm in most cases of ALS. In cultured neurons, including human stem-cell-derived motor neurons, TDP-43 molecules that fail to pair up meet a sensor called TBK1. That meeting turns on an interferon-beta signal, and nearby neurons then build an immunoproteasome that breaks the protein down before it aggregates. Checks in mice, and in spinal-cord tissue donated by people who had ALS, found the receptor for that signal much lower in the patient samples. Senior author Koji Yamanaka said interferon beta itself is a poor treatment because of side effects, and the next step is to look for other compounds that switch the same cleanup system on.

ALS still has few ways to slow the damage. A cleanup path the cells already have gives researchers a specific thing to try to restore.

Cell, mouse, and postmortem tissue work, not a trial of a new drug. The team says this path may run alongside autophagy, not in place of it.

Nagoya University ↗· Oct 20, 2026

Image: University of Bristol

Bristol scientists find a chicken immune cell that could steady flock vaccines

University of Bristol and Pirbright Institute researchers report, in the European Journal of Immunology, the first clear look at a chicken immune cell that behaves like the natural killer T cells mammals use for a fast response. The cells switch on only when they see both a fat molecule called GM3 and an alarm signal from other immune cells. Once on, they call in help against bacteria such as Salmonella and E. coli and can also destroy virus-infected cells. Senior author Shahriar Behboudi said the find changes how the bird immune system is understood. Co-author Nitin Kamble said the pathway looks shared across breeds, so a vaccine that includes a lipid such as GM3 might protect a flock more evenly.

Poultry vaccines do not always work the same way from breed to breed. A shared immune target is a practical place to start.

A laboratory discovery, not a vaccine tried in a flock. Less reliance on antibiotics is a hope the researchers stated, not a result of this study.

For a rare form of rectal cancer, an immunotherapy may replace surgery

On Monday the FDA granted accelerated approval for dostarlimab, sold as Jemperli, used alone in adults with previously untreated stage II or III rectal cancer whose tumors are mismatch-repair deficient or microsatellite instability-high. The agency says that pattern appears in about 3 percent of locally advanced rectal cancers. In the AZUR-1 study, 154 patients received up to nine doses over six months. After a median follow-up of more than two years, almost three-quarters had not gone on to surgery, radiation, or chemotherapy. An earlier Memorial Sloan Kettering study of 50 patients found no detectable cancer after the drug, and 93 percent of them were still clear at twelve months. Standard care at this stage often means chemotherapy and radiation before an operation that can change bowel, urinary, and sexual function. The drug can also turn the immune system on healthy organs. Fatigue, rash, diarrhea, and itching were each reported in at least 15 percent of patients treated for this cancer.

For a small group of patients, the chance to skip an operation that reshapes daily life is the news.

Accelerated approval, based on interim results, and only for this uncommon tumor pattern. The sponsor still has to show the benefit lasts. It does not apply to most rectal cancer.

Image: University of Twente

A transplanted Wadden Sea marsh lost only millimetres of ground under two-metre waves

Teams from the University of Twente, Deltares, Wageningen, NIOZ, Delft, and other labs moved intact salt marsh from the Peazemerlannen reserve on the Frisian Wadden Sea coast into the Delta Flume in Delft, a channel built to make very large artificial waves. They rebuilt more than 300 square metres of marsh and ran waves for about 29 hours, up to two metres high. After 21 hours the surface had dropped by about seven millimetres on average. Plants added a little extra calming: at 75 centimetres, 6 to 22 percent, and at two metres no more than 6 percent. Across species chosen to stand in for marshes elsewhere, about 30 percent of the plant material was lost, and at least a third of the plants were still standing. The papers are in Nature and Communications Sustainability. Where storm waves over a marsh stay near a metre, the team estimates plants can add more than 10 percent of the reduction, and in places up to 50 percent.

A marsh that holds its ground in a storm is a living edge a coast can keep, alongside the walls people build.

This was one transplanted marsh in a laboratory flume, not a storm on a living coast. The plants were damaged, and their extra help faded as the waves grew.

A personalized mRNA vaccine cut the risk of melanoma returning or death by 42%

In a phase III trial, the personalized mRNA vaccine intismeran, given with the immunotherapy pembrolizumab, was tied to a 42% lower risk of melanoma returning or the patient dying than pembrolizumab with a placebo. Nature reports that 1,137 people with moderate to advanced melanoma enrolled at 157 centres, after surgery to remove their tumours. Trial leader Georgina Long, of the Melanoma Institute Australia, said participants have been followed for about 25 months and will be watched for years to see whether the vaccine lengthens life. She said the therapy did not produce any major harmful side effects. Each dose is built from mutations in that person's tumour, so the immune system has a chance to recognize proteins the cancer cells make. The vaccine is meant to stop a return, not to keep someone from developing melanoma in the first place. Merck and Moderna released the figures after the data leaked on October 22. The full results are due at the European Society for Medical Oncology meeting in Madrid on October 24. Cancer geneticist Jessamy Tiffen said some people did not respond, and that two years is not the whole story.

For someone who has already had a melanoma removed, a vaccine made from their own tumour is a new way to ask the immune system to watch for a return.

The 42% figure combines recurrence and death. It is not a cure rate, and overall survival is still being counted. The conference presentation is Saturday, and some patients did not benefit. Nothing here shows the same vaccine would work in other cancers.

Nature ↗· Oct 23, 2026

An experimental drug stalled most treatment-resistant solid tumors in an early trial

The first human trial of invikafusp alfa, called invika, is reported in Nature Medicine by researchers at the National Cancer Institute, Mass General Brigham, and Memorial Sloan Kettering. The protein is built to stir only two narrow groups of tumor-infiltrating T cells, rather than T cells across the board. Most of the people enrolled had solid tumors that had already done poorly on immune checkpoint drugs such as pembrolizumab. In phase 1 the team varied the dose, given every two weeks. Flu-like side effects showed up and were generally handled with extra medicine and supportive care. At the dose they then carried into phase 2, 16 of 27 people had no further progression, and 4 of the 27 saw targeted tumors shrink by more than 30 percent. Two of those four had metastatic colorectal cancer and were on invika as a seventh treatment. Another had stage 4 non-small cell lung cancer that had already turned away several drugs. People on lower doses did not show a clear benefit. The authors tied the four shrinkages to the biggest shifts in the T cells the drug is meant to reach, and they note that immune activity did not always become a measurable change in the cancer. The sponsor, Marengo Therapeutics, has an FDA Fast Track designation for the drug in certain solid tumors after checkpoint therapy. The trial is still enrolling.

For someone whose tumor has already outlasted standard immunotherapy, a drug aimed at a smaller set of T cells is another thing to test, with the side effects so far looking more like a flu than a broad immune collapse.

These are early phase 1 and phase 2 results in 27 people at one dose, not a cure rate. Sixteen without progression is not the same as sixteen in remission. The trial is ongoing, and the authors say the next questions include combining invika with other treatments.

A pancreatic cancer vaccine woke an immune response in nearly every patient who could be measured

Mayo Clinic researchers report a phase 2 trial of an experimental vaccine aimed at seven common mutations in KRAS, a gene altered in about 90 percent of pancreatic ductal adenocarcinomas. Unlike a vaccine built from one person's tumor, this one is made in advance for anyone whose cancer carries a mutation it targets. The study, published in Nature Medicine, enrolled 144 people with stage 1 to 3 disease who had already had surgery and chemotherapy and had no cancer visible on scans. Ninety-six received the vaccine and 48 were observed. The trial missed its main goal. Median time before the cancer returned was 23.8 months with the vaccine and 21.2 months without it, a gap that was not statistically significant. Of 90 vaccinated patients who could be checked, 89 showed a stronger T-cell response against mutated KRAS. In an exploratory look, people with the stronger responses stayed free of disease longer. Signals also showed up in people with no tumor DNA detectable in the blood at the start, and in people who had not had radiation. Lead author Ben George said the immune response is a clue for a larger phase 3 trial, which is planned. Overall survival is not in yet.

Pancreatic cancer often returns after surgery. A vaccine the immune system can actually notice is a next experiment, even before anyone can say it changes how long people stay well.

The study did not show that the vaccine kept cancer away longer for the group as a whole. The link between a stronger immune response and longer disease-free survival is exploratory. Some findings apply only to subgroups. This is not a treatment available outside a trial.

Mayo Clinic ↗· Oct 23, 2026

Image: Science News

A new study lines the stars in The Starry Night up with a July dawn in 1889

Astronomer Elijah Jeong-hyun Kim and colleagues report in Scientific Reports that the sky in Vincent van Gogh's The Starry Night fits the hours just before dawn on 22 July 1889, over Saint-Rémy-de-Provence. They read the painted cluster as the Hyades, the sideways V in Taurus, and used a shape comparison called Procrustes analysis to score that match against other constellations. The moon in the painting is a sharp waning crescent, which does not match the waxing gibbous of 19 June, an earlier candidate. Venus sits in the same narrow view. Kim says he stood at the window in 2019 and saw the moon, the Hyades, and Venus of that July morning fall inside a drawing of the view. Art historians have long dated the canvas to mid-June, because van Gogh wrote his brother Theo on or about 18 June that he had a new study of a starry sky, and because he then fell ill and stopped painting for about six weeks. Donald Olson, an astronomer at Texas State who has worked on skies in paintings, says that letter is still the stronger evidence, and that the window frame the team used may not be the one van Gogh saw.

A painting people treat as pure dream may also be a careful look out of a hospital window, taken down to one morning.

This is one team's reconstruction, published on 22 October, and a specialist in the field disagrees. The June letter is van Gogh's. The fit is described as close, not perfect. The article does not claim the date of the painting is settled.

Science News ↗· Oct 22, 2026

Jumping spiders in a Bonn lab sleep in two stages, one of them twitchy and REM-like

Biologists at the University of Bonn say the Australian jumping spider Portia fimbriata really sleeps, and that the sleep comes in two stages. One of those stages looks like REM sleep: the eyes move and the muscles twitch. Nadja Geiger, Daniela Rößler, and colleagues filmed the spiders for days and nights in plastic dishes about 12 centimeters across, using infrared cameras after dark. They checked that the animals were actually asleep by playing a sound and timing how long a spider took to respond. They also kept the spiders up and watched them sleep longer afterward, the rebound people know from a short night. The release, put out on 26 October, calls this the first full experimental case that a spider's stillness is regulated sleep. Portia is a spider that hunts other spiders, about the size of a one-euro coin, and the team picked it because that hunting looks like learning. They did not record brain activity. Rößler and Geiger say the hard part was finding a sound the spiders would answer, and not reading too much into the twitches. The work is published in PNAS and was backed by the German Research Foundation.

A spider hanging still under its silk may be asleep in a way that is closer to ours than the stillness suggests.

The release is careful: the REM-like stage is judged from behavior, not from brain recordings, and only this species was tested, in dishes in a lab. The researchers say the twitches should not be overread. The piece does not claim the spiders dream.

Image: ScienceDaily (University of Michigan)

A liquid painted on a baby tooth stopped decay in more than half of the cavities in a large trial

ScienceDaily wrote on 25 October about a phase 3 trial of silver diamine fluoride, a liquid a dentist paints onto a cavity in seconds, with no drill, no injection, and no sedation. Researchers led by the University of Michigan enrolled 830 children younger than 6, through dental clinics, pediatric offices, and Head Start programs in Michigan, New York, and Iowa. Applied at six-month intervals, a 38 percent solution stopped decay in more than half of the treated baby teeth. Lead investigator Margherita Fontana called the treatment effective and safe even for children as young as 1. The silver stains the decayed part of the tooth black, which shows most on front teeth. It does not rebuild what has already been lost. It is meant to keep the damage from spreading. In the United States the FDA cleared the liquid in 2014 as a device for tooth sensitivity, and dentists have used it off label for cavities. Co-principal investigator Amr Moursi said the trial gives a manufacturer evidence for an application asking the FDA to approve it as a drug that arrests decay. That approval is not in hand.

A few seconds with a tiny brush can spare a small child a drill, if a family can live with a dark spot on a tooth that will fall out.

ScienceDaily's page is dated 25 October. The paper is in JAMA Pediatrics; the National Institutes of Health dates that publication to 27 July 2026, so this is a later writeup of the same trial. More than half is not every cavity, and the black stain is permanent on the decayed part. This is not an FDA approval for treating cavities, and it is not something a person paints on at home.

Image: Anthropocene Magazine

A compostable plastic with a little enzyme inside broke down on the deep-sea floor

Anthropocene Magazine wrote on 29 October about a Nature paper from a team in Japan. Compostable plastics are made to break down in a hot, humid compost heap. In cold seawater they can linger. The researchers melted four of them, PBS, PBSA, PCL, and PBAT, and folded in freeze-dried enzymes, a lipase and a cutinase, at very low doses, from 0.1 to 3 percent by weight. Films and tiny beads then went into mesh and into the sea off Tokyo, from a few metres down to 5,503 metres, for between a month and 18 months. At 757 metres, films of PBS, PBSA, and PCL that held 3 percent cutinase nearly disappeared within five months. At a tenth of a percent, those three lost 27.4 percent, 100 percent, and 85.5 percent of their mass in a month. PBAT lost just over 12 percent in the same test. Samples with no enzyme barely changed. Even on the cold floor of the deepest site, the enzyme plastics showed some breakdown. Beads with 0.1 percent cutinase grew visible pores and cracks within two weeks in coastal water. The team wrote that the embedding did not spoil the materials' strength.

A wrapper that can come apart in deep water is a design for the plastic that gets away, not a promise that the sea will tidy itself.

This is a field test of new materials, published in Nature on 21 October, not a product in shops and not a way to clear plastics already drifting. PBAT, one of the four, barely moved. The percentages are for specific films, depths, and enzyme doses. "Within weeks" fits the coastal beads, not every sample at every depth.

Image: McGill University Health Centre

A low-calorie diet plus supervised exercise put early type 2 diabetes into remission for 27 of 50 younger adults

The McGill University Health Centre wrote on 23 October about RESET for Remission, a trial led by Kaberi Dasgupta at the centre's research institute and Tom Yates at the University of Leicester, published in The Lancet Regional Health – Americas and presented at the European Association for the Study of Diabetes meeting in Milan. The trial enrolled 96 adults aged 18 to 45 who had type 2 diabetes and obesity and were not using insulin, at centres in Montreal, Edmonton, and Leicester. For 12 weeks, 50 of them ate 800 to 900 calories a day, mostly meal-replacement shakes and bars, and did aerobic and strength work twice a week with a supervisor and once on their own. For the next 12 weeks they moved to ordinary food meant to hold the loss, and kept exercising on their own. Remission meant blood sugar below the level used to diagnose diabetes, with no diabetes medicine for at least 12 weeks. Twenty-seven of the 50, 54 percent, reached that mark. Two of the 46 people in usual care did, about 4 percent. The centre said the programme group lost about 7.5 kilograms more than usual care, and that the loss was fat while fat-free mass held. Fitness rose about 10 percent relative to body weight, grip got stronger, and blood pressure and resting heart rate fell. They also reported fewer symptoms of low mood, less distress tied to diabetes, and a better quality of life. Early side effects, including constipation, headache, dizziness, and fatigue, eased. The paper, as the centre describes it, recorded no serious adverse events.

A few months of structured meals and someone counting the repetitions is a route back that does not start in an operating room.

This is six months in 96 people, not a cure and not a result for everyone with type 2 diabetes. There was no diet-only group, so the trial cannot separate the exercise from the calories or from the extra time with staff. It was open-label. People who needed insulin were not included. Follow-up stopped at 24 weeks, so the centre cannot say the remission lasts once the structure ends. The 7.5 kilogram figure is the centre's account of the adjusted difference.

A Sheffield technician remakes the colour-changing glass of a 1,600-year-old Roman cup

The University of Sheffield said on 26 October that technician Lisa Hollands has reproduced, in quantity, the dichroic glass of the Lycurgus Cup, a fourth-century Roman cup in the British Museum that looks jade green in reflected light and ruby red when lit from behind. Working with Roman glass expert Caroline Jackson, she built a base glass like the Romans might have used, then spent many trials adjusting furnaces, starting materials, oxygen levels, and even adding sugar, to get tiny particles of gold and silver to form the right way. Glass artist Elliot Walker used the recipe to blow a new sculpture that blends the Lycurgus story with the Farnese Atlas, a cup in place of the globe. It will be shown at the Millennium Gallery during the Festival of the Mind, 6 to 15 November, and then kept at the university's Turner Museum of Glass.

A patient bench experiment lets anyone in Sheffield see an ancient trick of light, not only those who visit one museum case.

The university calls this the first reproduction in quantity; people have made dichroic glass before with mixed success. Nobody knows exactly how the Romans did it, so the recipe is a modern route to the same effect, not a recovered Roman method.

Image: The University of Sydney

A honey bee hive arranges its honey, wax, pollen and propolis in layers that guard the young

The University of Sydney said researchers led by Kenya Fernandes sampled honey, pollen, beeswax, and propolis, the sticky plant resin bees use to seal cracks, from 24 colonies across five apiaries at Tocal College in New South Wales, and also studied the bees themselves. Writing in ISME Communications, they report that these materials are not scattered at random. The parts of the hive most exposed to the outside hold the strongest broad defences, such as hydrogen peroxide in honey and flavonoids in propolis. Closer to the centre, the wax comb, stored pollen, and the bees' own bodies become more selective, keeping out harmful bacteria and fungi while letting helpful ones live, much as a gut does. The strength of those defences tracked the plants around each apiary, so bushland and farmland hives differed.

A hive keeps its youngest safe with what the flowers nearby provide, which makes the case for a varied landscape.

Calling the hive an immune system is the researchers' comparison. The study covered European honey bees in one region of Australia; it shows how defences are arranged, not that more flowers would cure sick hives.

Image: ScienceDaily (INRAE)

Young poplars straighten their bent stems by growing a second set of muscle-like wood

ScienceDaily carried a release from INRAE, France's national agricultural research institute, on a study in New Phytologist. Plants can sense their own shape, but it was not clear how that sense becomes movement. Researchers laid young poplars on their sides until the stems curved upward, then moved them onto a slowly turning platform inside a sphere lit evenly from all sides, so the trees had no steady cue from gravity or light. The stems straightened over the following weeks. The pulling wood on the upper side stopped forming, and the same kind of wood began to grow on the opposite side, working like a pair of opposing muscles. The team says this could help breed straighter trees and cereals that are less likely to flatten before harvest.

Even a sapling has a quiet way of knowing when it is leaning and setting itself right.

This was a lab study on young poplars in an artificial setup. The uses for timber and crops are possibilities the researchers suggest, not results yet.